Venous Thromboembolism and Vascular Access Thrombosis in Patients on Hemodialysis: Incidence, Risk Factors, and Use of Antithrombotic Agents
Thrombosis and Haemostasis · 01.09.2026 · 126 (09) · 965-973
DOI: 10.1055/a-2700-6368 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.09.2026. Verfasst von Oliver Königsbrügge und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Renal Dialysis, Fibrinolytic Agents, Venous Thromboembolism, Kidney Failure, Chronic. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Austrian National Bank (Jubiläumsfond Österreichische Nationalbank, Joseph-Skoda-Prize of the Austrian Association of Internal Medicine, Austrian Science Fund.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Patients with end-stage kidney disease on hemodialysis (HD) have an increased risk of venous thromboembolism (VTE) and HD-specific vascular access thrombosis (VAT). We aimed to capture the incidence of VTE and VAT events and investigate risk factors for VTE and VAT occurrence, including antithrombotic agent use. Prevalent patients on maintenance HD were recruited into a prospective, population-based, observational cohort study in Vienna, Austria. During a maximum follow-up of 45 months, the occurrence of VTE, defined as deep vein thrombosis, catheter- or noncatheter-associated, and pulmonary embolism, or VAT, defined as thrombotic occlusion of an arteriovenous fistula or graft, was recorded. Risk factors for thrombotic events were analyzed by multivariable competing risk regression. VTE and VAT events occurred with an incidence rate of 1.7 (95% confidence interval [CI]: 1.2–2.6) and 7.6 per 100 person-years (95% CI: 6.3–9.3), respectively. The 30-day case fatality rates were 20.8 and 4.1% for VTE and VAT events, respectively. Prior VAT (hazard ratio [HR]: 3.07, 95% CI: 1.33–7.11, p = 0.009) and nephrectomy (HR: 6.53, 95% CI: 2.23–19.14, p = 0.001) were significantly associated with increased risk of VTE occurrence. Prior VAT was associated with a 1.8-fold (95% CI: 1.18–2.65, p = 0.006) and nephrectomy with a 2.8-fold increased risk of VAT occurrence (95% CI: 1.45–5.57, p = 0.002). Patients on vitamin K antagonists were protected from VTE (HR: 0.001, 95% CI:
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
- Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Aichi, Japan.
- Department of Medicine III, Clinic Donaustadt, Vienna, Austria.
- Department of Medicine I, Clinic Favoriten, Vienna, Austria.
- Vienna Dialysis Center, Vienna, Austria.
- Department of Medicine VI, Clinic Ottakring, Vienna, Austria.
Förderung
- Austrian National Bank (Jubiläumsfond Österreichische Nationalbank
- Joseph-Skoda-Prize of the Austrian Association of Internal Medicine
- Austrian Science Fund
- Special Research Program (SFB) 54
Zitieren
APA
Königsbrügge, O., Klauser-Braun, R., Schmaldienst, S., Lorenz, M., Pabinger, I., Säemann, M., & Ay, C. (2026). Venous Thromboembolism and Vascular Access Thrombosis in Patients on Hemodialysis: Incidence, Risk Factors, and Use of Antithrombotic Agents. Thrombosis and Haemostasis, 126(09), 965-973. https://doi.org/10.1055/a-2700-6368
Vancouver
Königsbrügge O, Klauser-Braun R, Schmaldienst S, Lorenz M, Pabinger I, Säemann M, et al. Venous Thromboembolism and Vascular Access Thrombosis in Patients on Hemodialysis: Incidence, Risk Factors, and Use of Antithrombotic Agents. Thrombosis and Haemostasis. 2026;126(09):965-973. doi:10.1055/a-2700-6368
BibTeX
@article{Knigsbrgge2026,
author = {Königsbrügge, Oliver and Klauser-Braun, Renate and Schmaldienst, Sabine and Lorenz, Matthias and Pabinger, Ingrid and Säemann, Marcus and Ay, Cihan},
title = {Venous Thromboembolism and Vascular Access Thrombosis in Patients on Hemodialysis: Incidence, Risk Factors, and Use of Antithrombotic Agents},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {09},
pages = {965--973},
doi = {10.1055/a-2700-6368}
}
EUVIMED